Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Futura Medical, a pharmaceutical group that develops products for consumer healthcare, has entered into a development agreement with GlaxoSmithKline Consumer Healthcare (GSK) to develop TPR100, a topically applied product for pain relief.
Subscribe to our email newsletter
As per the terms of the agreement GSK is expected to fully fund and be responsible for all clinical and regulatory development. Additionally, GSK is also expected to pay modest annual payments to Futura Medical as the development work proceeds.
Futura and GSK are now expecting to enter into a commercial distribution agreement subject to satisfactory clinical outcomes and regulatory approvals.
James Barder, CEO of Futura Medical, said: “This agreement marks another important step in the development of Futura. It broadens the company’s commercial relationships and sources of potential royalty income.
“In addition, it provides further endorsement of our DermaSys drug delivery technology and of our strengths in product development.”